Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2023-12-18 00:00:00 ET · period of report 2023-12-14 · accession 0001127602-23-029831 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-18 | 2023-12-14 | BCRX | Doyle Anthony | CFO | A - Grant | $0.00 | +34.0K | 235.4K | +17% | $0 |
| D | 2023-12-18 | 2023-12-14 | BCRX | Doyle Anthony | CFO | F - Tax | $6.43 | -5,475 | 229.9K | -2% | -$35.2K |
| D | 2023-12-18 | 2023-12-14 | BCRX | Doyle Anthony | CFO | A - Grant | $0.00 | +158.5K | 158.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-14 | A | A | 34,000 | $0.00 | 235,401 | D | — | — | (F1) Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Common | Common Stock | 2023-12-14 | F | D | 5,475 | $6.43 | 229,926 | D | — | — | (F2) Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. |
| 3 | Derivative | Emp. Stock Option (Right to Buy) | 2023-12-14 | A | A | 158,500 | $0.00 | 158,500 | D | $6.43 · 2024-12-14 to 2033-12-14 | 158,500 Common Stock | (F3) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |